601 related articles for article (PubMed ID: 32705213)
21. Integrated miRNA-mRNA Expression Profiles Revealing Key Molecules in Ovarian Cancer Based on Bioinformatics Analysis.
Li C; Hong Z; Ou M; Zhu X; Zhang L; Yang X
Biomed Res Int; 2021; 2021():6673655. PubMed ID: 34734085
[TBL] [Abstract][Full Text] [Related]
22. Data Mining of Differentially Expressed Genes in Ovarian Epithelial Carcinoma: Implications in Precise Medicine.
Zhao J; Gao H; He Y
Curr Top Med Chem; 2021 Oct; 21(14):1285-1300. PubMed ID: 34238161
[TBL] [Abstract][Full Text] [Related]
23. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
24. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
Wu M; Sun Y; Wu J; Liu G
Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
[TBL] [Abstract][Full Text] [Related]
25. Identification of Key Biomarkers and Potential Molecular Mechanisms in Renal Cell Carcinoma by Bioinformatics Analysis.
Li F; Guo P; Dong K; Guo P; Wang H; Lv X
J Comput Biol; 2019 Nov; 26(11):1278-1295. PubMed ID: 31233342
[No Abstract] [Full Text] [Related]
26. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
27. Integrated Analysis of Hub Genes and Pathways In Esophageal Carcinoma Based on NCBI's Gene Expression Omnibus (GEO) Database: A Bioinformatics Analysis.
Yu-Jing T; Wen-Jing T; Biao T
Med Sci Monit; 2020 Aug; 26():e923934. PubMed ID: 32756534
[TBL] [Abstract][Full Text] [Related]
28. Identification of Hub Genes and Pathways in Gastric Adenocarcinoma Based on Bioinformatics Analysis.
Qiu J; Sun M; Wang Y; Chen B
Med Sci Monit; 2020 Feb; 26():e920261. PubMed ID: 32058995
[TBL] [Abstract][Full Text] [Related]
29. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
[TBL] [Abstract][Full Text] [Related]
30. Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker.
Li C; Zhou D; Jiang X; Liu M; Tang H; Mei Z
Gene; 2019 May; 698():9-18. PubMed ID: 30825595
[TBL] [Abstract][Full Text] [Related]
31. Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
Li M; Zhang S; Ma Y; Yang Y; An R
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33846814
[TBL] [Abstract][Full Text] [Related]
32. In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1.
Khedkar HN; Wang YC; Yadav VK; Srivastava P; Lawal B; Mokgautsi N; Sumitra MR; Wu ATH; Huang HS
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072728
[TBL] [Abstract][Full Text] [Related]
33. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
Nitecki R; Fleming ND; Fellman BM; Meyer LA; Sood AK; Lu KH; Rauh-Hain JA
Gynecol Oncol; 2021 Jun; 161(3):660-667. PubMed ID: 33867146
[TBL] [Abstract][Full Text] [Related]
34. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
35. Investigation of hypoxia networks in ovarian cancer via bioinformatics analysis.
Zhang K; Kong X; Feng G; Xiang W; Chen L; Yang F; Cao C; Ding Y; Chen H; Chu M; Wang P; Zhang B
J Ovarian Res; 2018 Feb; 11(1):16. PubMed ID: 29482638
[TBL] [Abstract][Full Text] [Related]
36. Topological network analysis of differentially expressed genes in cancer cells with acquired gefitinib resistance.
Lee YS; Hwang SG; Kim JK; Park TH; Kim YR; Myeong HS; Kwon K; Jang CS; Noh YH; Kim SY
Cancer Genomics Proteomics; 2015; 12(3):153-66. PubMed ID: 25977174
[TBL] [Abstract][Full Text] [Related]
37. Tumor necrosis factor α-induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy.
Wang J; Gao H; Liu G; Gu L; Yang C; Zhang F; Liu T
Hum Pathol; 2018 Dec; 82():239-248. PubMed ID: 30107189
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis based gene expression profiling reveals functional genes in ovarian cancer.
Zhao L; Li Y; Zhang Z; Zou J; Li J; Wei R; Guo Q; Zhu X; Chu C; Fu X; Yue J; Li X
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33135729
[TBL] [Abstract][Full Text] [Related]
39. Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis.
Xu Z; Zhou Y; Cao Y; Dinh TL; Wan J; Zhao M
Med Oncol; 2016 Nov; 33(11):130. PubMed ID: 27757782
[TBL] [Abstract][Full Text] [Related]
40. Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments.
Zheng MJ; Li X; Hu YX; Dong H; Gou R; Nie X; Liu Q; Ying-Ying H; Liu JJ; Lin B
J Cell Physiol; 2019 Jul; 234(7):11023-11036. PubMed ID: 30633343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
